The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients:a cross-sectional study

References

• Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479.
   PubMed Web of Science ®Google Scholar
• Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin N Am. 1995;22:237–246.
   PubMed Web of Science ®Google Scholar
• Donnell RF. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol. 2011;21:22–26.
   PubMed Web of Science ®Google Scholar
• Partin AW, Oesterling JE, Epstein JI, et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145:405–409.
   PubMed Web of Science ®Google Scholar
• Vanella L, Russo GI, Cimino S, et al. Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia. Urology. 2014;83:7–13.
   Web of Science ®Google Scholar
• Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16:101–116.
   PubMed Web of Science ®Google Scholar
• Ploumidou K, Kyroudi-Voulgari A, Perea D, et al. Effect of a hypercholesterolemic diet on serum lipid profile, plasma sex steroid levels, and prostate structure in rats. Urology. 2010;76:1–5.
   Web of Science ®Google Scholar
• Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyper-insulinemia with benign prostate hyperplasia. Prostate. 2010;70:79–89.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–158.
   PubMed Web of Science ®Google Scholar
• Zou C, Gong D, Fang N, et al. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol. 2016;34:281–289.
   PubMed Web of Science ®Google Scholar
• Pashootan P, Ploussard G, Cocaul A, et al. Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort. BJU Int. 2015;116:124–130.
   PubMed Web of Science ®Google Scholar
• Russo GI, Castelli T, Urzì D, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Aging Male. 2015;18:207–216.
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12:29–34.
   PubMed Web of Science ®Google Scholar
• Yeh HC, Liu CC, Lee YC, et al. Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male. 2012;15:166–172.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008;101:313–318.
   PubMed Web of Science ®Google Scholar
• Chiu YL, Kao S, Lin HC, et al. Benign prostatic enlargement is not associated with diabetes: a population-based study. Andrology. 2015;3:933–936.
   PubMed Web of Science ®Google Scholar
• Martin S, Lange K, Haren MT, et al. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol. 2014;191:130–137.
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K, Gudbjörnsdottir S, Eliasson B, et al. The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract. 2014;106:136–144.
   PubMed Web of Science ®Google Scholar
• Hadaegh F, Khalili D, Ghasemi A, et al. Triglyceride/HDL cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis. 2009;19:401–408.
   PubMed Web of Science ®Google Scholar
• Soška V, Jarkovský J, Ravčuková B, et al. The logarithm of the triglyceride/HDL-cholesterol ratio is related to the history of cardiovascular disease inpatients with familial hypercholesterolemia. Clin Biochem. 2012;45:96–100.
   PubMed Web of Science ®Google Scholar
• Mills IW, Crossland A, Patel A, et al. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol. 2007;52:503–509.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng X, Dong L, et al. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol. 2015;33:2071–2077.
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Jacobsen SJ, Jacobson DJ, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int. 2011;107:443–450.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Meuleman EJ, Legros JJ, Bouloux PM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male. 2015;18:157–163.
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11:1567–1576.
   PubMed Web of Science ®Google Scholar
• Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008;11:146–149.
   PubMed Web of Science ®Google Scholar
• Kalinchenko S, Vishnevskiy EL, Koval AN, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008;11:57–61.
   PubMed Web of Science ®Google Scholar